These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39019012)

  • 41. Gilteritinib Inhibits Glutamine Uptake and Utilization in
    Zavorka Thomas ME; Lu X; Talebi Z; Jeon JY; Buelow DR; Gibson AA; Uddin ME; Brinton LT; Nguyen J; Collins M; Lodi A; Sweeney SR; Campbell MJ; Sweet DH; Sparreboom A; Lapalombella R; Tiziani S; Baker SD
    Mol Cancer Ther; 2021 Nov; 20(11):2207-2217. PubMed ID: 34518298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

  • 44. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
    He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
    Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.
    Ansari AS; Kucharski C; Kc R; Nisakar D; Rahim R; Jiang X; Brandwein J; Uludağ H
    Acta Biomater; 2024 Oct; 188():297-314. PubMed ID: 39236794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gilteritinib: First Global Approval.
    Dhillon S
    Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
    Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia.
    Ye L; Cui Z; Sun Y; Zhou H; Rong Q; Wang D; Jin J; Zhang Q; Kang D; Hu L; Wang J
    Bioorg Chem; 2024 Aug; 149():107477. PubMed ID: 38820938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
    Lam SSY; Leung AYH
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNA-based
    Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
    Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.
    Buelow DR; Bhatnagar B; Orwick SJ; Jeon JY; Eisenmann ED; Stromatt JC; Pabla NS; Blachly JS; Baker SD; Blaser BW
    Blood Adv; 2022 Sep; 6(17):5049-5060. PubMed ID: 35797240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
    Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
    J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gilteritinib or Chemotherapy for Relapsed or Refractory
    Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
    N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.